Paclitaxel Plus Carboplatin Deemed a New Standard for Uterine Carcinosarcoma
The median overall survival was similar between the treatment arms.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Racial Disparities Persist in Ovarian Cancer Treatment
Black race was significantly associated with not receiving a recommendation for chemotherapy.
Balstilimab Plus Zalifrelimab Produces Durable Responses in Advanced Cervical Cancer
The median duration of response was not reached at a median follow-up of 21 months.
Cervical Cancer Incidence Varies by Neighborhood Wealth
The poorest neighborhoods in New York City have cervical cancer rates 73% higher than the wealthiest neighborhoods.
AGO Score Identifies Ovarian Cancer Patients Likely to Benefit from Cytoreductive Surgery
Patients with a positive AGO score had better survival outcomes with surgery plus chemotherapy, compared with chemotherapy alone.
Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence and mortality were greater for patients aged 15-24 years than for those aged 25-39 years.
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions.
Maintenance Olaparib Provides Long-Term PFS Benefit in Ovarian Cancer
The median PFS was 56.0 months with olaparib and 13.8 months with placebo.
Unemployment Adversely Linked to Recommended Cancer Screening
Unemployed adults were less likely to be up to date on screening for cervical, breast, colorectal, and prostate cancer.
Cervical Cancer, CIN3 in Young Women Plummeted After HPV Vaccination
There were 448 fewer cervical cancers and 17,235 fewer CIN3 cases than expected.
Gemogenovatucel-T Maintenance Provides Lasting Benefit in HRP Ovarian Cancer
Gemogenovatucel-T improved recurrence-free and overall survival at 3 years.
Pre-Existing CHIP Variants Tied to Therapy-Related Neoplasms in Ovarian Cancer
TP53 CHIP variants were significantly more common in patients with therapy-related myeloid neoplasms.
Changes in BMI, Weight Linked to Survival in Endometrial Cancer
Changes in weight and BMI were associated with disease-free and overall survival.
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Neoadjuvant Chemotherapy May Reduce Short-Term Mortality in Advanced Ovarian Cancer
Patients treated at facilities with a high use of neoadjuvant chemotherapy had greater declines in 1-year mortality rates over time.
Overall Cancer Incidence, Mortality Lower for U.S. Hispanics
Higher rates of infection-related cancers were seen among Hispanic individuals.
Pembrolizumab Monotherapy Promising for MSI-H Advanced Endometrial Cancer
The duration of response was more than 3 years in 68% of patients.
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced Endometrial Cancer
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
Tivdak Approved for Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 women with recurrent or metastatic cervical cancer.
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
Loading... 
Loading...